Truist Securities Maintains Buy on Medline, Lowers Price Target to $47

Benzinga Newsdesk www.benzinga.com Negative 57.8%

Neg 57.8% Neu 0% Pos 0%

Truist Securities analyst Jailendra Singh maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $56 to $47.